Report in English with a Dutch summary (KCE reports 45A)
Report in English with a Dutch summary (KCE reports 45A) Report in English with a Dutch summary (KCE reports 45A)
34 Screening for Colorectal Cancer KCE reports vol.45 3 RISK STRATIFICATION FOR COLORECTAL CANCER 3.1 INTRODUCTION The majority, about 70 - 75% of patients with colorectal cancer, have sporadic disease, with no apparent evidence of having inherited the disorder. The remaining 25 - 30% of patients has a family history of colorectal cancer that suggests a genetic contribution, common exposures among family members, or a combination of both 47. Limiting screening or early cancer detection to only these persons at increased risk would obviously miss the majority of colorectal cancers. Specific genetic mutations have been identified as the cause of inherited cancer risk in some CRC-prone families. High penetrance dominant genes yielding clinical syndromes such as familial adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer (HNPCC - Lynch syndrome) are estimated to account for approximately 5% to 6% of colorectal cancer cases overall 48, 47. It is likely that other yet undiscovered major genes and background genetic factors contribute to the development of colorectal cancer. Moderate familial clustering, on the other hand, represents a heterogeneous group attributable to a combination of genes, environment, and chance. This chapter does not deal with personal lifestyle, dietary nor environmental risk factors. An excellent overview of these aspects can be found in the SIGN National clinical guideline on management of colorectal cancer 49, on the National Cancer Institute website 38 (USA) or on the Australian Cancer Network website 50. 3.2 PERSONAL AND FAMILIAL HISTORY ELEMENTS INDICATING INCREASED CRC RISK Patients with the following history are to be considered as having a moderateto-high lifetime risk of developing CRC51-54, 29, 55, 27, 56-58: 3.2.1 Personal history of adenomatous polyps A personal history of adenomatous polyps is associated with an increased risk of future development of additional polyps and of colorectal cancer. This risk increases with sizes greater than 1 cm for any adenomatous polyp, the number of polyps, and villous or tubulovillous histology 59-62. Efforts to identify causes of CRC and to develop effective preventive measures have led to the hypothesis that adenomatous polyps (adenomas) are precursors for the vast majority of colorectal cancers. Evidence supporting the adenomacarcinoma sequence in colorectal cancer is summarized in Table 5 63.
KCE reports vol.45 Screening for Colorectal Cancer 35 Table 5: Evidence Supporting the Adenoma Carcinoma Sequence in Colorectal Cancer 63 1. Adenomas and carcinomas are frequently contiguous 2. The anatomical distribution of adenomas and carcinomas is similar 3. Adenomas > 2 cm in diameter have a 50% risk of harboring invasive malignancy The prevalence of adenomas is similar to that of carcinomas, and the average age of 4. adenoma patients is about five years younger In about one third of all surgical specimens resected for carcinoma, synchronous 5. adenomas will be found 6. Familial adenomatous polyposis (FAP) is unequivocally premalignant Adenomas and carcinomas share similar patterns of chromosomal abnormality and 7. 8. genetic mutation There is indirect but strong evidence that colonoscopy and polypectomy are associated with a reduced incidence of carcinoma In effect, measures which reduce the incidence and prevalence of adenomas may result in a subsequent decrease in the risk of colorectal cancer 64. In addition, the National Polyp Study (US) data suggest that adenoma prevalence results from a dynamic process of both formation as well as regression of adenomas 65. All publicatons 59, 60, 66, 67, 61, 62 concur on: 1. Patients with only one or two tubular adenomas < 1 cm with only low-grade dysplasia should have their next follow-up colonoscopy in 5 to 10 years. The precise timing within this interval should be based on other clinical factors (such as prior colonoscopy findings, family history, and the preferences of the patient and judgment of the physician). 2. Patients with 3 to 10 adenomas, or any adenoma > 1 cm, or any adenoma with villous features, or high-grade dysplasia should have their next follow-up colonoscopy in 3 years provided that piecemeal removal has not been done and the adenoma(s) are completely removed. 3. Patients who have more than 10 adenomas at one examination should be examined at a shorter (< 3 years) interval established by clinical judgment, and the clinician should consider the possibility of an underlying familial syndrome. 4. Patients with sessile adenomas 67 that are removed piecemeal should be considered for follow up at short intervals (2 to 6 months) to verify complete removal. Once complete removal has been established, subsequent surveillance needs to be individualized based on the endoscopist s judgment. Completeness of removal should be based on both endoscopic and pathologic assessments. 5. Patients with small rectal hyperplastic polyps should be considered to be at average risk, and therefore the interval before the subsequent colonoscopy should be 10 years. An exception is patients with a hyperplastic polyposis syndrome 66. They are at increased risk for adenomas and colorectal cancer and need to be identified for more intensive follow up.
- Page 1 and 2: Health Technology Assessment Colore
- Page 3 and 4: Health Technology Assessment Colore
- Page 5 and 6: KCE reports vol.45A Colorectale Kan
- Page 7 and 8: KCE reports vol.45A Colorectale Kan
- Page 9: KCE reports vol.45A Colorectale Kan
- Page 12 and 13: 2 Screening for Colorectal Cancer K
- Page 14 and 15: 4 Screening for Colorectal Cancer K
- Page 16 and 17: 6 Screening for Colorectal Cancer K
- Page 18 and 19: 8 Screening for Colorectal Cancer K
- Page 20 and 21: 10 Screening for Colorectal Cancer
- Page 22 and 23: 12 Screening for Colorectal Cancer
- Page 24 and 25: 14 Screening for Colorectal Cancer
- Page 26 and 27: 16 Screening for Colorectal Cancer
- Page 28 and 29: 18 Screening for Colorectal Cancer
- Page 30 and 31: 20 Screening for Colorectal Cancer
- Page 32 and 33: 22 Screening for Colorectal Cancer
- Page 34 and 35: 24 Screening for Colorectal Cancer
- Page 36 and 37: 26 Screening for Colorectal Cancer
- Page 38 and 39: 28 Screening for Colorectal Cancer
- Page 40 and 41: 30 Screening for Colorectal Cancer
- Page 42 and 43: 32 Screening for Colorectal Cancer
- Page 46 and 47: 36 Screening for Colorectal Cancer
- Page 48 and 49: 38 Screening for Colorectal Cancer
- Page 50 and 51: 40 Screening for Colorectal Cancer
- Page 52 and 53: 42 Screening for Colorectal Cancer
- Page 54 and 55: 44 Screening for Colorectal Cancer
- Page 56 and 57: 46 Screening for Colorectal Cancer
- Page 58 and 59: 48 Screening for Colorectal Cancer
- Page 60 and 61: 50 Screening for Colorectal Cancer
- Page 62 and 63: 52 Screening for Colorectal Cancer
- Page 64 and 65: 54 Screening for Colorectal Cancer
- Page 66 and 67: 56 Screening for Colorectal Cancer
- Page 68 and 69: 58 Screening for Colorectal Cancer
- Page 70 and 71: 60 Screening for Colorectal Cancer
- Page 72 and 73: 62 Screening for Colorectal Cancer
- Page 74 and 75: 64 Screening for Colorectal Cancer
- Page 76 and 77: 66 Screening for Colorectal Cancer
- Page 78 and 79: 68 Screening for Colorectal Cancer
- Page 80 and 81: 70 Screening for Colorectal Cancer
- Page 82 and 83: 72 Screening for Colorectal Cancer
- Page 84 and 85: 74 Screening for Colorectal Cancer
- Page 86 and 87: 76 Screening for Colorectal Cancer
- Page 88 and 89: 78 Screening for Colorectal Cancer
- Page 90 and 91: 80 Screening for Colorectal Cancer
- Page 92 and 93: 82 Screening for Colorectal Cancer
34 Screen<strong>in</strong>g for Colorectal Cancer <strong>KCE</strong> <strong>reports</strong> vol.45<br />
3 RISK STRATIFICATION FOR COLORECTAL<br />
CANCER<br />
3.1 INTRODUCTION<br />
The majority, about 70 - 75% of patients <strong>with</strong> colorectal cancer, have sporadic<br />
disease, <strong>with</strong> no apparent evidence of hav<strong>in</strong>g <strong>in</strong>herited the disorder. The<br />
rema<strong>in</strong><strong>in</strong>g 25 - 30% of patients has a family history of colorectal cancer that<br />
suggests a genetic contribution, common exposures among family members, or<br />
a comb<strong>in</strong>ation of both 47. Limit<strong>in</strong>g screen<strong>in</strong>g or early cancer detection to only<br />
these persons at <strong>in</strong>creased risk would obviously miss the majority of colorectal<br />
cancers.<br />
Specific genetic mutations have been identified as the cause of <strong>in</strong>herited cancer<br />
risk <strong>in</strong> some CRC-prone families. High penetrance dom<strong>in</strong>ant genes yield<strong>in</strong>g<br />
cl<strong>in</strong>ical syndromes such as familial adenomatous polyposis (FAP) and hereditary<br />
non-polyposis colorectal cancer (HNPCC - Lynch syndrome) are estimated to<br />
account for approximately 5% to 6% of colorectal cancer cases overall 48, 47. It is<br />
likely that other yet undiscovered major genes and background genetic factors<br />
contribute to the development of colorectal cancer.<br />
Moderate familial cluster<strong>in</strong>g, on the other hand, represents a heterogeneous<br />
group attributable to a comb<strong>in</strong>ation of genes, environment, and chance.<br />
This chapter does not deal <strong>with</strong> personal lifestyle, dietary nor environmental<br />
risk factors. An excellent overview of these aspects can be found <strong>in</strong> the SIGN<br />
National cl<strong>in</strong>ical guidel<strong>in</strong>e on management of colorectal cancer 49, on the<br />
National Cancer Institute website 38 (USA) or on the Australian Cancer<br />
Network website 50.<br />
3.2 PERSONAL AND FAMILIAL HISTORY ELEMENTS<br />
INDICATING INCREASED CRC RISK<br />
Patients <strong>with</strong> the follow<strong>in</strong>g history are to be considered as hav<strong>in</strong>g a moderateto-high<br />
lifetime risk of develop<strong>in</strong>g CRC51-54, 29, 55, 27, 56-58:<br />
3.2.1 Personal history of adenomatous polyps<br />
A personal history of adenomatous polyps is associated <strong>with</strong> an <strong>in</strong>creased risk<br />
of future development of additional polyps and of colorectal cancer. This risk<br />
<strong>in</strong>creases <strong>with</strong> sizes greater than 1 cm for any adenomatous polyp, the number<br />
of polyps, and villous or tubulovillous histology 59-62.<br />
Efforts to identify causes of CRC and to develop effective preventive measures<br />
have led to the hypothesis that adenomatous polyps (adenomas) are precursors<br />
for the vast majority of colorectal cancers. Evidence support<strong>in</strong>g the adenomacarc<strong>in</strong>oma<br />
sequence <strong>in</strong> colorectal cancer is summarized <strong>in</strong> Table 5 63.